©The Author(s) 2025.
World J Gastrointest Oncol. Aug 15, 2025; 17(8): 109646
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.109646
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.109646
Table 4 Multi-factor Cox regression analysis
| Variable | Z | HR (95%CI) | P value |
| Differentiation | |||
| Well | Reference | ||
| Moderate | 1.573 | 1.516 (0.903, 2.545) | 0.116 |
| Poorly | 2.678 | 1.848 (1.179, 2.896) | 0.007 |
| cN stage | |||
| Negative | Reference | ||
| Positive | 2.872 | 1.794 (1.204, 2.672) | 0.004 |
| cTNM | |||
| II | Reference | ||
| IIIA | 1.100 | 1.493 (0.731, 3.048) | 0.271 |
| IIIB | 4.213 | 2.477 (1.625, 3.778) | < 0.001 |
| IIIC | 5.834 | 3.750 (2.405, 5.846) | < 0.001 |
| RECIST 1.1 | |||
| Ineffective | Reference | ||
| Effective | -3.259 | 0.574 (0.411, 0.802) | 0.001 |
| TRG | |||
| Ineffective | Reference | ||
| Effective | 2.580 | 2.008 (1.182, 3.410) | 0.010 |
| Tumor diameter | |||
| ≤ 2 | Reference | ||
| 2-5 | 3.453 | 1.974 (1.342, 2.903) | 0.001 |
| ≥ 5 | 5.282 | 3.145 (2.056, 4.811) | < 0.001 |
- Citation: Wang YC, Zhang CG, Wang YW, Guo C, Pan T, Yu PJ, Cai BJ, Ding RH, Qiang JL, Deng CQ, Hu CH, Xu YH. SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety. World J Gastrointest Oncol 2025; 17(8): 109646
- URL: https://www.wjgnet.com/1948-5204/full/v17/i8/109646.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i8.109646